RegulatoryCompany release

Rani Therapeutics' RaniPill platform accepted into FDA Emerging Technology Program

🇺🇸 Rani Therapeutics Holdings, Inc. (RANI) · Mon 09 Nov 2026

The oral biologics developer also reported $45.3 million in cash at the end of Q3 2026, which it expects to fund operations through at least the end of 2027.

Rani Therapeutics Holdings said its RaniPill Capsule platform was accepted in October into the US Food and Drug Administration's CDER Emerging Technology Program. The company disclosed the news on 9 November 2026 alongside its third-quarter results.

The programme lets participating companies engage with the agency early on technical, manufacturing and regulatory questions linked to novel technologies. Rani stressed that acceptance does not constitute approval of the platform or of any product that uses it.

On the clinical side, enrolment continues in the expansion cohort of the Phase 1a study of RT-114. The company expects to report data from that cohort by the end of 2026.

Rani reported cash of $45.3 million at the end of the third quarter. It expects this to fund operations through at least the end of 2027.

What it means for your team

  • Acceptance into the Emerging Technology Program gives Rani an early channel to FDA on technical, manufacturing and regulatory issues, but it is not an approval or a signal of one.
  • Teams tracking novel oral delivery of biologics should note that Rani's RT-114 Phase 1a expansion data are due by the end of 2026.
  • Rani's stated cash runway through at least the end of 2027 covers the period in which it is engaging with the FDA and generating early clinical data.

Company's press release (SEC filing): Rani Therapeutics Holdings, Inc. ↗

Article written by VigiEye from the official source (Rani Therapeutics Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →